0000899243-20-034340.txt : 20201217
0000899243-20-034340.hdr.sgml : 20201217
20201217203012
ACCESSION NUMBER: 0000899243-20-034340
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201215
FILED AS OF DATE: 20201217
DATE AS OF CHANGE: 20201217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hayden Michael R
CENTRAL INDEX KEY: 0001352908
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39781
FILM NUMBER: 201397706
MAIL ADDRESS:
STREET 1: C/O ASPREVA PHARMACEUTICALS CORPORATION
STREET 2: 1203-4464 MARKHAM STREET
CITY: VICTORIA
STATE: A1
ZIP: V8Z 7X8
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbCellera Biologics Inc.
CENTRAL INDEX KEY: 0001703057
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2215 YUKON STREET
CITY: VANCOUVER
STATE: A1
ZIP: V5Y 0A1
BUSINESS PHONE: (604) 559-9005
MAIL ADDRESS:
STREET 1: 2215 YUKON STREET
CITY: VANCOUVER
STATE: A1
ZIP: V5Y 0A1
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-15
0
0001703057
AbCellera Biologics Inc.
ABCL
0001352908
Hayden Michael R
C/O ABCELLERA BIOLOGICS INC.
2215 YUKON STREET
VANCOUVER
A1
V5Y 0A1
BRITISH COLUMBIA, CANADA
1
0
0
0
Common Shares
2020-11-06
4
M
0
270000
0.33
A
985750
I
See footnote
Common Shares
2020-12-15
4
C
0
117647
A
1103397
I
See footnote
Common Shares
2020-12-15
4
P
0
73665
20.00
A
118245
I
By spouse
Stock Option (right to buy)
0.33
2020-11-06
4
M
0
270000
0.00
D
2029-09-11
Common Shares
270000
540000
I
See footnote
Stock Option (right to buy)
2.76
2020-11-18
4
A
0
100000
0.00
A
2030-11-18
Common Shares
100000
100000
D
Convertible Note
2020-12-11
4
A
0
2000000.00
2000000.00
A
Common Shares
117647
2000000.00
I
See footnote
Convertible Note
17.00
2020-12-15
4
C
0
2000000.00
0.00
D
Common Shares
117647
0
I
See footnote
These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.
On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
The exercise price reported above was converted from the Canadian exercise price of CAD $0.43 using an exchange rate of CAD $1.27840 = US $1.00.
50% of the shares subject to such option vest and become exercisable on September 11, 2021 and 50% of the shares subject to such option vest and become exercisable on September 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date.
The exercise price reported above was converted from the Canadian exercise price of CAD $3.52 using an exchange rate of CAD $1.27840 = US $1.00.
100% of the shares subject to such option vest and become exercisable on the date of the 2021 annual general meeting of the Issuer, subject to the Reporting Person's continuous service to the Issuer on such date
The convertible promissory note ("Convertible Note") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the Issuer's initial public offering into Common Shares at a conversion price equal to $17.00 per Common Share.
This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
/s/ Tryn Stimart, attorney-in-fact
2020-12-17